The Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $608,126 to the Regents of the University of Minnesota to fund the discovery and validation of single-cell biomarkers for clinical outcomes in sickle cell disease. The key products and services to be delivered under this grant include:
-
Defining the relationship between common sickle cell disease adverse clinical outcomes and single-cell biochemical and mechanical properties to identify the most promising biomarkers.
-
Defining the relationship between favorable and unfavorable responses to sickle cell disease treatments and single-cell biochemical and mechanical properties to identify the most promising biomarkers.
-
Developing a platform to measure kinetic changes in single red blood cell properties during deoxygenation and identifying kinetic metrics that correlate with clinical outcomes in sickle cell disease.
The overall goal is to develop a set of validated biomarkers that can be used to proactively predict the odds of adverse events and monitor response to new therapies for sickle cell disease in a rapid, objective, and quantitative manner. This project grant was awarded on December 15, 2024 with an ultimate completion date of November 30, 2028.
Generated 1/28/25, 8:47 AM